Sobi, Innate partnership for lacutamab becomes effective with $75 million payment
AI Summary- Sobi and Innate made their lacutamab strategic partnership effective.
- Sobi will pay Innate $75 million when the agreement becomes effective.
- TELLOMAK-3's first patient is expected in Q1 2027, Innate said.